25 result(s) displayed (1 - 25 of 29):
Pfizer Inc. (NYSE:PFE) employees concerned about their jobs may have a better idea of where they stand. The pharmaceutical giant on Monday announced plans to consolidate 20 R&D centers into five central hubs as part of its integration of Wyeth. This Pfizer press release provides a complete list of facilities...
Posted on November 10, 2009 10:45 AM
The approval by U.S. antitrust regulators of Pfizer Inc.'s (NYSE:PFE) acquisition of Wyeth is an outlier of how merger reviews will be conducted under the Obama administration. That's according to Jeffrey Schmidt, a partner with Linklaters and a former director of the Federal Trade Commission's office of competition under President...
Posted on November 6, 2009 3:50 PM
On Wednesday, Pfizer Inc. (NYSE:PFE) received approval from the FTC for its $68 billion acquisition of Wyeth. Friday is Day One for the combined companies. The mood at the two giant organizations no doubt varies by function and location. But a juxtaposition of two facts in a Bloomberg report suggests...
Posted on October 16, 2009 10:50 AM
The approval by Chinese regulators of Pfizer Inc.'s (NYSE:PFE) $68 billion merger with Wyeth (NYSE:WYE) earlier this week offers another glimpse into just how open China will be to foreign investment under its new anti-monopoly law. The conditional clearance -- under which Pfizer will have to divest certain animal health assets in...
Posted on October 1, 2009 3:27 PM
In the long winding road from "secret merger talks" to deal completion, bankers, lawyers and corporate dealmakers alike breathe easier when their hard work is met with regulatory and shareholder approvals along the way. Collecting fees is also a source of comfort. Sure, they get money from retainer and reimbursement...
Posted on July 17, 2009 3:01 PM
In a broader effort to focus on its human pharmaceutical business and raise cash (as well as investor confidence), Indian generic drug maker Wockhardt Ltd. is selling its animal health division to France's Vétoquinol. The deal marks Vétoquinol's entrance into India. Earlier this month, Wockhardt sold its German business Esparma...
Posted on June 29, 2009 3:29 PM
Wyeth's (NYSE:WYE) head of pharmaceutical research Mikael Dolsten has already accepted a job at Pfizer Inc. (NYSE:PFE), which is buying his company for $68 billion, but at an industry conference in San Francisco on Wednesday he barely mentioned his new boss as he touted several drugs in Wyeth's pipeline. In...
Posted on June 17, 2009 2:57 PM
Pfizer Inc.'s (NYSE:PFE) $68 billion acquisition of Wyeth (NYSE:WYE) and Merck & Co.'s (NYSE:MRK) $41 billion bid for Schering Plough Corp. (NYSE:SGP) sparked fresh speculation on whether pharma megamergers create value and whether industry consolidation would continue. We've done our share of analysis. Recently, Baz Hiralal posted this solid roundup...
Posted on June 2, 2009 2:46 PM
How's this for a sign of the times: One of the most innovative drug industry deals of the year involves the biggest firm of them all, Pfizer Inc. (NYSE:PFE), but it isn't its $68 billion takeover of Wyeth. Instead, the pundits at Windhover Research's In Vivo blog say Pfizer is...
Posted on May 27, 2009 3:00 PM
Does a business model combining pharmaceutical drugs and consumer products make for good corporate strategy? It's a question nearly every pharma giant has considered at one point or another. Well, the findings of a new study from pharmacy benefits management provider Medco Health Solutions adds another data point to the...
Posted on May 13, 2009 1:34 PM
London-based pharma market intelligence report publisher URCH Publishing, which itself recently acquired pharma research firm Spectra Intelligence, is making predictions about who among the top 10 pharmas will follow in the footsteps of the sector's three biggest deals this year, with Bristol-Myers Squibb Co. (NYSE:BMY), Bayer AG and Novartis...
Posted on April 23, 2009 9:14 AM
The healthcare industry is restructuring itself to reduce its reliance on blockbuster drugs while trying to gain a foothold in the generics market and the emerging markets. We've seen megamergers and bolt-ons, and there's more to come. New York boutique investment bank Centerview Partners LLC is right on top of...
Posted on April 15, 2009 12:47 PM
After Pfizer Inc. (NYSE:PFE) completes its $68 billion acquisition of Wyeth in the third quarter, it will retain eight senior executives from Wyeth and create two distinct research organizations to capitalize on their respective strengths in pharma and biotech.A Wall Street Journal report points out that previous Pfizer deals have...
Posted on April 7, 2009 1:14 PM
The latest Corporate Dealmaker column is up on our Deal magazine site. It's a look at the prime consumer brands, including Dr. Scholl's, that may or may not remain a part of the pharma behemoths being formed in the two big deals announced in the first quarter. The deals, of...
Posted on April 1, 2009 12:30 PM
Pfizer Inc. (NYSE:PFE) CEO Jeff Kindler says he admires the decentralized, diversified business models of Johnson & Johnson (NYSE:JNJ) and Abbott Laboratories (NSYE:ABT), and that he expects Pfizer's pending acquisition of Wyeth to make it more like those companies. He made the remarks in an interview with Bloomberg published Tuesday....
Posted on February 24, 2009 1:01 PM
Pfizer Inc. hopes to close its $68 billion deal to buy Wyeth by the end of 2009. To get there it will have to pass muster with antitrust regulators and credit agencies. Then the real work of integration begins. In this edition of Inside The Deal, Robbert van Batenburg, head...
Posted on February 16, 2009 12:53 PM
To those who ask if Pfizer Inc.'s proposed $68 billion acquisition of Wyeth represents the same kind of short-term remedy as the company's past megadeals, CEO Jeff Kindler (pictured) has been giving a consistent answer: We're different now.Kindler expanded on the theme in an interview with The Associated Press that...
Posted on February 9, 2009 10:35 AM
The latest Knowledge at Wharton newsletter explores Pfizer Inc.'s proposed $68 billion bid for Wyeth in a lengthy Q&A with healthcare professor Patricia Danzon and marketing professor Jagmohan Raju. The two professors discuss deal rationale, short- and long-term benefits, job cuts, integration (which our Kenneth Klee explored previously) and the...
Posted on February 5, 2009 11:20 AM
On Monday we were hankering to know more about how the combination of Pfizer Inc. and Wyeth into the most massive pharma company yet would square with the company's press release promise of a "flexible and unique" business model. According to the In Vivo blog (yes, we do link to...
Posted on January 28, 2009 11:40 AM
Tokyo's Astellas Pharma Inc. took to the newswires and made another unsolicited bid to acquire CV Therapeutics Inc. of Palo Alto, Calif. The $16 per share ($1 billion) offer is Astellas' second attempt in three months at buying the heart drugmaker. Perhaps it feels the timing is better with Pfizer...
Posted on January 27, 2009 9:26 AM
Industry observers have been saying for years that the blockbuster-driven, marketing-intensive business model for Big Pharma is obsolete, and that the companies who use it have some serious rethinking and restructuring to do. An article by a trio of Bain & Co. consultants, published in 2003, is still relevant. One...
Posted on January 26, 2009 2:28 PM
Stocks rose in part on the news of Pfizer Inc.'s $68 billion acquisition of rival Wyeth, which could prompt further consolidation in healthcare. While the synergistic deal would provide Pfizer with a broader range of products and help make up for the loss of patent protection for its cash cow...
Posted on January 26, 2009 12:48 PM
Pharma industry experts (including ours, for Pipeline subscribers) will be weighing in on this over the course of the day -- and well beyond if the talks about Pfizer Inc. buying Wyeth, reported in The Wall Street Journal and Financial Times this morning, bear fruit.Meanwhile, a few quick thoughts on...
Posted on January 23, 2009 10:08 AM
Big Pharmas are cutting costs; Bristol-Myers Squibb Co., Wyeth, Pfizer, Merck & Co., Schering-Plough Corp. and GlaxoSmithKline plc have all announced reductions in their U.S. sales forces. They're also worrying about life under the Democrats.Do they still want to replenish their pipelines with high-priced biotech drugs? James Greenwood, president and...
Posted on November 20, 2008 4:23 PM
Biotech giant Amgen Inc. wants to buy, and it has the money to do so. Bloomberg.com reported that Amgen has $9.76 billion in cash and marketable securities -- the healthcare sector's third-biggest cash hoard, behind only Pfizer Inc.'s $26.2 billion and Wyeth's $13.5 billion.A spokesman told Bloomberg that Amgen sees...
Posted on November 5, 2008 3:53 PM
1
2
Next
Movable Type search results powered by Fast Search
Juergen Lasowski
And the winners are...
